瑞士制药巨头诺华集团（Novartis）周五公布，2024年第四季度销售额好于预期，但全年业绩低于预期。

　　按固定汇率计算，该公司第四季度净销售额增长16%，至132亿美元，高于分析师平均预期的127.95亿美元。

　　调整后的核心营业利润为48.6亿美元，高于预期的42.3亿美元。

　　2024年全年，按固定汇率计算，该公司的净销售额增长12%，达到503.2亿美元，略低于预期的504.7亿美元。全年核心营业利润增长22%至195亿美元，高于预期的170.2亿美元。

　　该公司表示，销售增长主要是由其畅销的心力衰竭药物Entresto和关节炎药物Cosentyx推动的。

　　该公司还概述了其2025年的业绩指引，预测净销售额将实现“中到高个位数”增长，核心营业利润将实现“高个位数至低两位数”增长。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：于健 SF069

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.